Clinical Benefits of Inhibition of Cholesterol Absorption for Japanese Patients with Dyslipidaemia

2007 ◽  
Vol 1 (1) ◽  
pp. 11
Author(s):  
Masafumi Kitakaze ◽  
Keyword(s):  
Japanese Patients ◽  
Cholesterol Absorption ◽  
Clinical Benefits

scholarly journals Erlotinib-induced Adverse Skin Reactions

2013 ◽  
Vol 6 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Toshiyuki Yamamoto
Keyword(s):  
Growth Factor Receptor ◽  
Japanese Patients ◽  
Skin Lesions ◽  
Outer Root Sheath ◽  
Skin Reactions ◽  
Cutaneous Manifestations ◽  
Acneiform Eruption ◽  
Common Skin ◽  
Clinical Benefits ◽  
Domain Block

Erlotinib is low molecular-weight quinazolin derivatives which selectively inhibit the epidermal growth factor receptor (EGF-R) tyrosine kinase activity of the intracellular domain, block autophosphorylation and the subsequent signaling cascades. EGF-R is expressed on basal keratinocytes, sebocytes, the outer root sheath of hairs, and endothelial cells in the skin, and plays important roles in the regulation of differentiation, proliferation, apoptosis, attachment and migration of keratinocytes, inflammation, and wound healing. Therefore, inhibition of EGF-R causes a number of cutaneous adverse reactions. Among them, severe skin lesions are very stressful, and impair quality of life of patients. Moreover, they even bring disadvantages such as drug withdrawal or interruption. Several review papers describe representative or common skin lesions which appear either during the first a few weeks or at later phases. Common skin manifestations include papular and pustular follicular eruptions (acneiform eruption), xerosis, paronychia, pruritus, and abnormalities of hairs; however, other than those eruptions, several unusual lesions are also induced. Early intervention of dermatologists and management of skin lesions are quite important, because discontinuance of the drug is unfavorable for patients with clinical benefits for cancers. In this brief review, various cutaneous manifestations seen in Japanese patients treated with erlotinib (Tarceva) are shown, and current management of representative severe conditions is also described.

Clinical benefits of long-term use of sorafenib in Japanese patients with unresectable renal cell carcinoma (RCC)

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16039-16039 ◽  
Author(s):  
S. Naito ◽  
T. Tsukamoto ◽  
M. Murai ◽  
K. Fukino ◽  
K. Nakajiima ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Japanese Patients ◽  
Clinical Benefits

Clinical Benefits and Tolerability of Increased Fill Volumes in Japanese Peritoneal Dialysis Patients

2001 ◽  
Vol 21 (5) ◽  
pp. 455-461 ◽  
Author(s):  
Atsushi Fukatsu ◽  
Yasuhiro Komatsu ◽  
Hachiro Senoh ◽  
Hironobu Miyai ◽  
Yoshinori Tanaka ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Effective Means ◽  
Random Order ◽  
Japanese Patients ◽  
Double Blind Study ◽  
Double Blind ◽  
Patient Tolerance ◽  
Fill Volume ◽  
Clinical Benefits ◽  
Solute Clearance

Background Increasing fill volume is an effective means of improving clearances in patients on peritoneal dialysis (PD). Since Japanese PD patients are physically smaller than their Western counterparts, there is some concern that PD patients in Japan may be unable to tolerate larger fill volumes. Objective To determine patient tolerance and changes in solute clearance and net ultrafiltration resulting from increased fill volumes in Japanese patients on PD. Design Prospective double-blind study, randomizing patients to three different fill volumes (2.5% dextrose solution: 1.5 L, 2.0 L, or 2.5 L) administered in random order on three different occasions separated by 1 week. Results Twenty-one patients with a mean age of 55.4 ± 2.1 years and a mean body surface area of 1.66 ± 0.03 m2 were studied. On a scale of 0 to 10, patients’ mean discomfort scores were 2.14 ± 0.59, 3.48 ± 0.54, and 3.81 ± 0.63 ( p = 0.047) at the end of the 1.5-L, 2.0-L, and 2.5-L dwells, respectively. There were no reports of cramps or shortness of breath with any fill volume. Patients were able to correctly guess the actual fill volume for only 34 of the 63 total exchanges (54.0%). Increasing fill volume resulted in an incremental improvement in peritoneal creatinine clearance, from 3.74 ± 0.16 to 4.49 ± 0.21 ( p < 0.001, 2.0 L vs 1.5 L) to 5.12 ± 0.20 mL/minute ( p < 0.001, 2.5 L vs 2.0 L) for 1.5-L, 2.0-L, and 2.5-L dwells, respectively. Peritoneal urea clearance also increased significantly, from 5.65 ± 0.13 to 7.04 ± 0.17 ( p < 0.001, 2.0 L vs 1.5 L) and 8.16 ± 0.29 mL/minute ( p < 0.001, 2.5 L vs 2.0 L), with incremental increases in fill volume. Similarly, net ultrafiltration in a 4-hour dwell increased significantly with fill volume, from 255.24 ± 24 mL with 1.5 L, to 356 ± 24 ( p < 0.004, 2.0 L vs 1.5 L) and 392 ± 29 mL ( p < 0.086, 2.5 L vs 2.0 L) in patients receiving 2.0 L and 2.5 L, respectively. Conclusion Increasing the fill volume results in improvement in solute clearance and net ultrafiltration in Japanese PD patients, with minimal increase in patient discomfort. A large percentage of patients were unable to identify the actual fill volume.

scholarly journals The Effects of Ezetimibe on Surrogate Markers of Cholesterol Absorption and Synthesis in Japanese Patients with Dyslipidemia

2010 ◽  
Vol 17 (1) ◽  
pp. 106-114 ◽  
Author(s):  
Shinya Hiramitsu ◽  
Yoshiaki Ishiguro ◽  
Hiroyuki Matsuyama ◽  
Kenji Yamada ◽  
Kazuo Kato ◽  
...  
Keyword(s):  
Japanese Patients ◽  
Cholesterol Absorption ◽  
Surrogate Markers

Efficacy of budesonide TurbuhalerR compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma

Respirology ◽  
2001 ◽  
Vol 6 (1) ◽  
pp. 27-35 ◽  
Author(s):  
Terumasa Miyamoto ◽  
Terumi Takahashi ◽  
Shigenori Nakajima ◽  
Sohei Makino ◽  
Michio Yamakido ◽  
...  
Keyword(s):  
Beclomethasone Dipropionate ◽  
Persistent Asthma ◽  
Japanese Patients

75: Sacral Neuromodulation: Cost Considerations and Clinical Benefits

2007 ◽  
Vol 177 (4S) ◽  
pp. 26-27
Author(s):  
Dennis H. Kim ◽  
Jocelyn M. Rieder ◽  
Eugene Y. Rhee ◽  
Shawn A. Menefee ◽  
Michael H. Ree ◽  
...  
Keyword(s):  
Sacral Neuromodulation ◽  
Clinical Benefits
Sign in / Sign up

Export Citation Format

Share Document